![John Jordan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
John Jordan has held positions as a Chief Financial Officer and Director at Rna Diagnostics, Inc. and as a Director and Chief Financial Officer at Proteocyte Diagnostics, Inc. Currently, Mr. Jordan holds positions at both companies as their Chief Financial Officer and Director.
Actieve functies van John Jordan
Bedrijven | Functie | Begin |
---|---|---|
Rna Diagnostics, Inc.
![]() Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada. | Financieel Directeur/CFO | - |
Proteocyte Diagnostics, Inc.
![]() Proteocyte Diagnostics, Inc. Medical SpecialtiesHealth Technology Proteocyte Diagnostics, Inc. develops prognostic oral precancer laboratory, which objectively and accurately detects oral lesions. The company was founded in 2011 and is headquartered in Toronto, Canada. | Financieel Directeur/CFO | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Rna Diagnostics, Inc.
![]() Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada. | Health Technology |
Proteocyte Diagnostics, Inc.
![]() Proteocyte Diagnostics, Inc. Medical SpecialtiesHealth Technology Proteocyte Diagnostics, Inc. develops prognostic oral precancer laboratory, which objectively and accurately detects oral lesions. The company was founded in 2011 and is headquartered in Toronto, Canada. | Health Technology |